TerminatedPhase 4

Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients

Stopped: Unable to enroll patients, no longer at institution.

United States2 participantsStarted 2014-09

Plain-language summary

The goal of this study is to evaluate the benefit of ACTH (Acthar) in reducing proteinuria associated with transplant glomerulopathy in non-diabetic kidney transplant recipients.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Kidney transplant recipients with confirmed transplant glomerulopathy on kidney biopsy. * Failed standard therapy (\>25% reduction in proteinuria) including maximum use of an ACE inhibitor, ARB, or aldosterone blocker with a goal blood pressure less than 130/80 and optimization of their immunosuppression Exclusion Criteria: * Diabetes

What they're measuring

50% Reduction in Proteinuria or Proteinuria < 150mg/Day

Timeframe: 6 months

Trial details

NCT IDNCT02057523

SponsorUniversity of Illinois at Chicago

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-03

Results submitted2020-08-20

View on ClinicalTrials.gov More Proteinuria trials